内皮素-1 A型受体免疫治疗用于肺动脉高压
该研究筛选出靶向内皮素-1 A型受体(ETAR)第二胞外环表位ETR-002的ETRQβ-002疫苗,并在MCT及Sugen/缺氧诱导的肺动脉高压动物模型中评估其疗效。结果显示疫苗及单克隆抗体可降低右心室收缩压、改善肺小动脉重构与右心室肥厚,且未检测到明显免疫介导损伤。
要点
- ETRQβ-002疫苗可诱导针对ETAR表位的特异性抗体产生。
- 疫苗及单抗在MCT大鼠和Sugen/缺氧小鼠中降低右心室收缩压。
- 疫苗及单抗改善肺小动脉重构和右心室肥厚,未见明显免疫损伤。
核心结论
- ETRQβ-002疫苗/单抗通过抑制ET-1启动的信号转导,减轻MCT和Sugen/缺氧诱导的PAH动物肺小动脉及右心室重构,并有效降低右心室收缩压。
- ETRQβ-002疫苗/单抗可能为PAH治疗提供一种新方法。
研究设计与样本
- 研究筛选ETRQβ-002疫苗,制备针对ETAR第二胞外环表位ETR-002的多克隆和单克隆抗体。
- 体外研究抗体对Ca2+依赖信号转导事件的影响。
- 体内用ETRQβ-002疫苗接种MCT诱导和Sugen/缺氧诱导的肺动脉高压动物,并向PAH动物注射抗ETR-002单抗。
- 评估疫苗对肺动脉高压及肺小动脉和右心室重构的影响,并在正常疫苗接种动物中检测可能的免疫介导损伤。
主要发现
- ETR-002肽具有良好免疫原性,ETRQβ-002疫苗可诱导强抗体产生。
- 体外抗ETR-002抗体结合ETAR,抑制ET-1诱导的细胞外信号调节激酶磷酸化和细胞内Ca2+浓度升高。
- 体内ETRQβ-002疫苗和单抗在MCT暴露大鼠中使右心室收缩压降低达20 mm Hg,在Sugen/缺氧暴露小鼠中降低达10 mm Hg。
- ETRQβ-002疫苗/单抗明显改善PAH动物肺小动脉病理重构和右心室肥厚。
- 疫苗接种动物中未检测到明显免疫介导损伤。
临床怎么用
- 该疫苗/单抗策略在动物模型中显示可降低右心室收缩压并改善肺血管和右心室重构,但尚未在人体中验证。
局限性
- 研究仅基于MCT和Sugen/缺氧诱导的动物模型,未提供人体数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pulmonary arterial hypertension (PAH) is a chronic fatal disease. The treatment of PAH is less than ideal and the control is far from satisfactory worldwide. Vaccination provides a promising approach for treatment of PAH. OBJECTIVES: This study sought to find a vaccine against endothelin-1 (ET-1) receptor type A (ETAR) for treating PAH. METHODS: The ETRQβ-002 vaccine was screened and the specific antibodies against epitope ETR-002 belonging to the second extracellular loop of ETAR (including the polyclonal and monoclonal antibody) were produced. The effect of the antibodies on Ca2+-dependent signal transduction events was investigated. In vivo, ETRQβ-002 vaccine was used to vaccinate monocrotaline (MCT)- and Sugen/hypoxia-induced pulmonary hypertension animals. The monoclonal antibody (mAb) against ETR-002 was also injected into the PAH animals. The effect of ETRQβ-002 vaccine on pulmonary hypertension and remodeling of pulmonary arterioles and right ventricle (RV) was carefully evaluated. Further, the possible immune-mediated damage was detected in normal vaccinated animals. RESULTS: ETR-002 peptide has perfect immunogenicity and ETRQβ-002 vaccine could induce strong antibody production. In vitro, the anti-ETR-002 antibody bound to ETAR and inhibited Ca2+-dependent signal transduction events, including extracellular signal-regulated kinase phosphorylation and elevation of intracellular Ca2+ concentration induced by ET-1. In vivo, both ETRQβ-002 vaccine and the mAb significantly decreased the RV systolic pressure up to 20 mm Hg and 10 mm Hg in MCT-exposed rats and Sugen/hypoxia-exposed mice, respectively. Also, ETRQβ-002 vaccine/mAb obviously ameliorated pathological remodeling of pulmonary arterioles and hypertrophy of the RV in PAH animals. Additionally, no significant immune-mediated damage was detected in vaccinated animals. CONCLUSIONS: ETRQβ-002 vaccine/mAb attenuated remodeling of pulmonary arterioles and RV in MCT- and Sugen/hypoxia-induced PAH animals and decreased RV systolic pressure effectively through diminishing the pressure response and inhibiting signal transduction initiated by ET-1. ETRQβ-002 vaccine/mAb may provide a novel and promising method for PAH treatment.
引用
- Dai Y, Chen X, Song X, et al. Immunotherapy of Endothelin-1 Receptor Type A for Pulmonary Arterial Hypertension. J Am Coll Cardiol. 2019. PMID: 31118151. doi:10.1016/j.jacc.2019.02.067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。